Chemical Genomics-Based Antifungal Drug Discovery: Targeting Glycosylphosphatidylinositol (GPI) Precursor Biosynthesis
Paul A. Mann(Merck & Co., Inc., Rahway, NJ, USA (United States)), Terry Roemer(Merck Canada Inc. (Canada)), Sandra Koseoglu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jennifer Nielsen Kahn(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xinwei Sher(Merck & Co., Inc., Rahway, NJ, USA (United States)), Olga Genilloud(Fundación Medina), Charlie Boone(University of Toronto), Kristine Devito(Merck & Co., Inc., Rahway, NJ, USA (United States)), Qian Si(Merck & Co., Inc., Rahway, NJ, USA (United States)), Amy Flattery(Merck & Co., Inc., Rahway, NJ, USA (United States)), Guy H. Harris(Merck & Co., Inc., Rahway, NJ, USA (United States)), Elena Kuzmin(University of Toronto), Michael Costanzo(University of Toronto), Charles G. Garlisi(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bo Jiang(University of Science and Technology of China), Hao Wang(Beijing Institute of Genomics), Nuria de Pedro(Fundación Medina), Catherine A. McLellan(Howard Hughes Medical Institute), Susan Lindquist(Howard Hughes Medical Institute), Nicholas Murgolo(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 86
Related Papers
New developments in RiPP discovery, enzymology and engineering
|Natural Product Reports|2020|793